Brokerages expect Flex Pharma Inc (NASDAQ:FLKS) to post ($0.85) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for Flex Pharma’s earnings. The lowest EPS estimate is ($1.42) and the highest is ($0.53). Flex Pharma reported earnings of ($0.41) per share in the same quarter last year, which would suggest a negative year over year growth rate of 107.3%. The business is scheduled to announce its next earnings results on Wednesday, March 14th.

On average, analysts expect that Flex Pharma will report full-year earnings of ($2.40) per share for the current fiscal year, with EPS estimates ranging from ($3.23) to ($2.08). For the next fiscal year, analysts expect that the company will report earnings of ($2.44) per share, with EPS estimates ranging from ($3.68) to ($1.42). Zacks’ earnings per share averages are an average based on a survey of research analysts that that provide coverage for Flex Pharma.

Flex Pharma (NASDAQ:FLKS) last issued its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($0.54) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.60) by $0.06. Flex Pharma had a negative return on equity of 71.39% and a negative net margin of 2,655.19%. The company had revenue of $0.41 million during the quarter, compared to analysts’ expectations of $0.47 million.

A number of analysts have commented on the company. Roth Capital reaffirmed a “buy” rating and set a $12.00 price target on shares of Flex Pharma in a research report on Wednesday. Zacks Investment Research cut Flex Pharma from a “hold” rating to a “sell” rating in a research report on Wednesday. Finally, Cantor Fitzgerald reiterated a “hold” rating and set a $10.00 price objective on shares of Flex Pharma in a research note on Monday, November 6th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $9.35.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Ameriprise Financial Inc. raised its stake in shares of Flex Pharma by 10.0% during the 3rd quarter. Ameriprise Financial Inc. now owns 720,524 shares of the biotechnology company’s stock valued at $2,457,000 after buying an additional 65,699 shares during the last quarter. Royce & Associates LP increased its stake in shares of Flex Pharma by 29.0% in the 2nd quarter. Royce & Associates LP now owns 312,410 shares of the biotechnology company’s stock valued at $1,203,000 after purchasing an additional 70,210 shares in the last quarter. Finally, Sphera Funds Management LTD. purchased a new position in shares of Flex Pharma in the 3rd quarter valued at about $2,341,000. Institutional investors and hedge funds own 27.31% of the company’s stock.

Shares of Flex Pharma (FLKS) traded up $0.26 on Tuesday, reaching $3.86. The company’s stock had a trading volume of 133,272 shares, compared to its average volume of 56,750. Flex Pharma has a 12 month low of $2.68 and a 12 month high of $5.93. The firm has a market cap of $70.84 and a PE ratio of -1.91.

ILLEGAL ACTIVITY WARNING: This report was first reported by Marea Informative and is the property of of Marea Informative. If you are viewing this report on another domain, it was copied illegally and reposted in violation of U.S. & international copyright law. The correct version of this report can be accessed at

Flex Pharma Company Profile

Flex Pharma, Inc is a biotechnology company. The Company develops treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise associated muscle cramps (EAMCs). The Company’s product candidates activate certain receptors in primary sensory neurons, which then act through neuronal circuits to reduce the repetitive firing, or hyperexcitability, of alpha-motor neurons in the spinal cord, thereby preventing or reducing the frequency and intensity of muscle cramps and spasms.

Get a free copy of the Zacks research report on Flex Pharma (FLKS)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Flex Pharma (NASDAQ:FLKS)

Receive News & Ratings for Flex Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flex Pharma and related companies with's FREE daily email newsletter.